超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

澳大利亞HealthLinx  
HealthLinx是對重點發展的新型血液中有未滿足市場需求，有針對性的疾病診斷的生物標志物和診斷開發公司。

卵巢癌的計劃已在2008年完成第二階段的生物標志物的試驗，篩選出150患病樣本和正常樣本212結果與發展OvPlex的?卵巢癌的診斷，針對癥狀的婦女。從多國多中心試驗的中期結果，在2011年底公布的市場，有超過740的樣本，在一個全球性的招聘活動，涉及在澳大利亞，新加坡和英國的醫生使用。 HealthLinx平臺套件是面向快速識別，開發和驗證生物標志物診斷中的應用，以及保健品和治療線索。雖然平臺是適用于各種各樣的疾病跡象，HealthLinx最初集中在卵巢癌。

HealthLinx’s suite of platforms is oriented towards the rapid identification, development and validation of biomarkers for diagnostic application as well as nutraceutical and therapeutic leads. Although the platforms are applicable to a wide variety of disease indications, HealthLinx has focused initially on ovarian cancer.

The company’s business model is to develop multi marker diagnostics for disease indications that have un-met market needs to a phase II biomarker trial achieving statistical significant results and releasing the products in the Australian market. Now that the product has been launched in Australia, the company is developing partnerships with distributors in other jurisdictions who will complete all regulatory requirements for mass distribution of OvPlex?. The company is also seeking to collaborate with research groups and clinical trial groups to use the assays as surrogate markers in clinical trials and research programs. This will allow for the capture of additional independent data to further validate the panels and generate revenue.